At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 205 enrolled
Drug / intervention
Izokibep +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating Izokibep and Placebo to izokibep for Hidradenitis Suppurativa. Completed, enrolled 205 participants across 44 sites in 6 countries.
Detailed Summary
Izokibep is a potent and selective inhibitor of interleukin 17A (IL-17A) that is being developed for treatment of hidradenitis suppurativa (HS). This study will evaluate the efficacy, safety, and immunogenicity of izokibep administered subcutaneously (SC) in adult subjects with moderate to severe HS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesCanada, Germany, Hungary, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMay 2022
Enrollment StartMay 2022
Primary CompletionAug 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedMay 2, 2022
Enrollment StartMay 5, 2022
Primary CompletionAug 2, 2023
Study CompletionFeb 21, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.2 years ago
Interventions
Izokibepdrug
Biologic: IL-17A inhibitor Form: Solution for injection Route of administration: Subcutaneous (SC)
Placebo to izokibepdrug
Form: Solution for injection Route of administration: Subcutaneous (SC)